» Articles » PMID: 34054812

Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature

Overview
Journal Front Immunol
Date 2021 May 31
PMID 34054812
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Gastric cancer (GC) still represents the third leading cause of cancer-related death worldwide. Peritoneal relapse (PR) is the most frequent metastasis occurring among patients with advanced gastric cancer. Increasingly more evidence have clarified the tumor immune microenvironment (TIME) may predict survival and have clinical significance in GC. However, tumor-transcriptomics based immune signatures derived from immune profiling have not been established for predicting the peritoneal recurrence of the advanced GC.

Methods: In this study, we depict the immune landscape of GC by using transcriptome profiling and clinical characteristics retrieved from GSE62254 of Gene Expression Omnibus (GEO). Immune cell infiltration score was evaluated single-sample gene set enrichment (ssGSEA) analysis algorithm. The least absolute shrinkage and selection operator (LASSO) Cox regression algorithm was used to select the valuable immune cells and construct the final model for the prediction of PR. The receiver operating characteristic (ROC) curve and the Kaplan-Meier curve were used to check the accuracy of PRIs. Gene Set Enrichment Analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were performed to explore the molecular pathways associated with PRIs.

Results: A peritoneal recurrence related immune score (PRIs) with 10 immune cells was constructed. Compared to the low-PRIs group, the high-PRIs group had a greater risk. The upregulation of the focal adhesion signaling was observed in the high-PRIs subtype by GSEA and KEGG. Multivariate analysis found that both in the internal training cohort and the internal validation cohort, PRIs was a stable and independent predictor for PR. A nomogram that integrated clinicopathological features and PRIs to predict peritoneal relapse was constructed. Subgroup analysis indicated that the PRIs could obviously distinguish peritoneal recurrence in different molecular subtypes, pathological stages and Lauren subtypes, in which PRIs of Epithelial-Mesenchymal Transitions (EMT) subtype, III-IV stage and diffuse subtype are higher respectively.

Conclusion: Overall, we performed a comprehensive evaluation of the immune landscape of GC and constructed a predictive PR model based on the immune cell infiltration. The PRIs represents novel promising feature of predicting peritoneal recurrence of GC and sheds light on the improvement of the personalized management of GC patients after surgery.

Citing Articles

Tumor-Stroma Ratio is a Critical Indicator of Peritoneal Metastasis in Gastric Cancer.

Zhong L, Huang H, Hou D, Zhou S, Lin Y, Yu Y Clin Exp Gastroenterol. 2025; 18():11-24.

PMID: 39867580 PMC: 11766153. DOI: 10.2147/CEG.S482377.


Diagnostic and prognostic value of the gasdermins in gastric cancer.

Xu Y, Chen J, Wang P, Chen H, Zhao Y, Cao X Braz J Med Biol Res. 2024; 57:e13817.

PMID: 39607202 PMC: 11653469. DOI: 10.1590/1414-431X2024e13817.


Clinical implications of CT-detected ascites in gastric cancer: association with peritoneal metastasis and systemic inflammatory response.

Xu M, Liu D, Wang L, Sun S, Liu S, Zhou Z Insights Imaging. 2024; 15(1):237.

PMID: 39373781 PMC: 11460829. DOI: 10.1186/s13244-024-01818-1.


Dissecting the Mechanisms of Intestinal Immune Homeostasis by Analyzing T-Cell Immune Response in Crohn's Disease and Colorectal Cancer.

Jiang T, Zheng J, Li N, Li X, He J, Zhou J Curr Gene Ther. 2024; 24(5):422-440.

PMID: 38682449 DOI: 10.2174/0115665232294568240201073417.


Complementary biomarkers of computed tomography for diagnostic grading of gastric cancer: DSCC1 and GINS1.

Zhu Y, Hou S, Kang C Aging (Albany NY). 2024; 16(5):4149-4168.

PMID: 38301047 PMC: 10968684. DOI: 10.18632/aging.205491.


References
1.
Wculek S, Malanchi I . Author Correction: Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature. 2019; 571(7763):E2. DOI: 10.1038/s41586-019-1328-7. View

2.
Zhang K, Yang G, Wu W, Zhang J, Xia X, Jiang T . Decreased Expression of Caveolin-1 and E-Cadherin Correlates with the Clinicopathologic Features of Gastric Cancer and the EMT Process. Recent Pat Anticancer Drug Discov. 2016; 11(2):236-44. DOI: 10.2174/1574892811666160128151437. View

3.
Senbanjo L, Chellaiah M . CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells. Front Cell Dev Biol. 2017; 5:18. PMC: 5339222. DOI: 10.3389/fcell.2017.00018. View

4.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

5.
Kim J, Lee J, Kang M, Jeong Y, Choi J, Oh S . Withaferin A Inhibits Helicobacter pylori-induced Production of IL-1β in Dendritic Cells by Regulating NF-κB and NLRP3 Inflammasome Activation. Immune Netw. 2016; 15(6):269-77. PMC: 4700403. DOI: 10.4110/in.2015.15.6.269. View